CLOVER HEALTH INVESTMENTS, CORP. /DE
CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) has a dated report snapshot, but its current priced-in claim is temporarily suppressed because the live engine record is unavailable or has changed.
• Clover Health is a Medicare Advantage insurer built around a clinical software layer (Clover Assistant), and the distinctive fact is that it has finally turned the corner on profitability: Q1 2026 brought GAAP net income of $27.3 million on revenue of $749.2 million, up 62.1% year over year [Source: Q1 2026 earnings release]. • The biggest risk is what the price asks for: at roughly eight times book value, the stock sits at the very top of its managed-care peer group, paying a multiple of net
Is CLOV overvalued? See what's priced in →
198 institutional managers reported holding CLOV in 13F filings for the quarter ended 2026-03-31. Together they hold about 24% of the company; the top 10 hold 18%. 39 opened new positions that quarter. Held by BlackRock, Vanguard Group, Geode Capital, among others. On the short side, 24.9M shares were sold short as of the 2026-06-15 count, about 5% of shares outstanding (2.5 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
CLOV's share count grew 27.9% over the past five years even with $47.52M spent on repurchases. It pays no dividend. Cash returned over the past three years: $37.61M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at CLOV over the trailing three years: 2023: 3 buys totaling $14k; 2024: 7 buys totaling $2.14M; 2025: 4 buys totaling $1.07M. 15 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
CLOV's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-05-10 | +4.5% | 0.0% |
| 2023-08-09 | +10.3% | -22.3% |
| 2023-11-07 | -15.6% | +4.3% |
| 2024-03-15 | +2.5% | +11.3% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
CLOV's latest 8-K filings: 2026-07-17 (items 8.01); 2026-06-18 (items 8.01); 2026-06-16 (items 5.02); 2026-06-12 (items 5.07); 2026-06-10 (items 8.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.